To develop innovative and safe multivalent anti-opioid vaccines that protect against heroin and fentanyl.
Active Definitive Contract Awarded Last action
- Contract number
- 75N93020C00038
- Awardee
-
The Children's Hospital Corporation UEI Z1L9F1MM1RY3
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $19,894,862
Award facts
- Opportunity
-
- Development of Vaccines for the Treatment of Opioid Use Disorder Pre-Solicitation · BAADAIT75N93019R009 · Posted Mar 5, 2019
- Development of Vaccines for the Treatment of Opioid Use Disorder Award Notice · Posted Sep 3, 2020
- Contract value 80% obligated
-
- $19,894,862.00 Current, with exercised options
- $24,785,826.00 Potential, with all options
- Completion date 87% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 9 offers Negotiated Proposal / Quote
- Pricing
- Cost No Fee
- Place of performance
- Boston, MA 02115, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $6,205,001 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $6,097,584 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $7,592,277 |
Show all 12
About this award
The National Institute of Allergy and Infectious Diseases awarded a $24.8 million definitive contract to The Children's Hospital Corporation (doing business as Boston Children's Hospital) for development of innovative and safe multivalent anti-opioid vaccines protecting against heroin and fentanyl, with a ceiling date of September 29, 2027. The contract carries no set-aside designation and is priced on a cost, no-fee basis.
The originating solicitation, posted March 5, 2019 with proposals due September 18, 2019, solicited vaccine development through early clinical trials, targeting high-affinity antibodies to prevent opioids from crossing the blood-brain barrier. Vaccine targets may include downstream metabolites. Place of performance is Boston, MA.
The source indicates an anticipated base period of 12 months with 4 option years exercisable through 2024, though the ultimate completion date reflects subsequent adjustment to September 2027. NAICS 325414 (Pharmaceutical Preparation Manufacturing) and PSC R421 apply.
In FY2024, the most recent reported fiscal year, the contract engaged 12.5 FTEs across 25,973 contractor hours, invoiced at $4.8 million, yielding a derived government-paid hourly rate of $183.47/hr. The prime self-performed all reported labor; no subcontractors were reported. Pricing has trended upward across the contract's life, rising from $145.52/hr in FY2021 to $183.47/hr in FY2024.
Quick answers
Who was awarded contract 75N93020C00038?
75N93020C00038 was awarded to The Children's Hospital Corporation by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 30, 2020.
How much is contract 75N93020C00038 worth?
The government has obligated $19,894,862 on 75N93020C00038. Its potential value, with all options, is $24,785,826.
Was contract 75N93020C00038 competed?
The extent of competition for 75N93020C00038 was full and open competition. The government received 9 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award